Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.60 |
| ▸ | MET | P08581 | 1/20 | 0.60 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.57 |
| ▸ | ALK | Q9UM73 | 14/20 | 0.54 |
| ▸ | INSR | P06213 | 3/20 | 0.53 |
| ▸ | IGF1R | P08069 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25305117 | 0.94 | EGFR (0.63) | EGFRMETZAP70ALKINSR | |
| SCHEMBL25259557 | 0.93 | EGFR (0.66) | EGFRMETZAP70ALKINSR | |
| SCHEMBL30497491 | 0.90 | EGFR (0.62) | EGFRMETZAP70ALK | |
| SCHEMBL26495833 | 0.90 | EGFR (0.62) | EGFRMETZAP70ALK | |
| SCHEMBL25306937 | 0.89 | EGFR (0.61) | EGFRMETZAP70ALKINSR | |
| SCHEMBL25308133 | 0.89 | EGFR (0.63) | EGFRMETZAP70ALKINSR | |
| SCHEMBL25262384 | 0.89 | EGFR (0.62) | EGFRMETZAP70ALK | |
| SCHEMBL25263290 | 0.88 | EGFR (0.61) | EGFRMETZAP70ALK | |
| SCHEMBL25261631 | 0.88 | EGFR (0.63) | EGFRMETZAP70ALKINSR | |
| SCHEMBL25304267 | 0.88 | EGFR (0.63) | EGFRMETZAP70ALKINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322723-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H BIOTECH INC. (KR) | 2023-10-12 | — | — | US | disclosed |
| EP-4212522-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H Biotech Inc. (KR) | 2023-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322723-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | EGFR, KRAS, ERBB2 | EGFR 1/4885MET 14/4885ZAP70 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.